.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Covington
Novartis
Deloitte
Mallinckrodt
McKinsey
Daiichi Sankyo
Healthtrust
Medtronic
Dow

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022260

« Back to Dashboard
NDA 022260 describes VELETRI, which is a drug marketed by Actelion Pharms Ltd and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the VELETRI profile page.

The generic ingredient in VELETRI is epoprostenol sodium. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the epoprostenol sodium profile page.

Summary for NDA: 022260

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 022260

Ingredient-typeProstaglandins I
Physiological EffectVasodilation

Suppliers and Packaging for NDA: 022260

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VELETRI
epoprostenol sodium
 INJECTABLE;INJECTION 022260 NDA Actelion Pharmaceuticals US, Inc. 66215-401 66215-401-01 1 VIAL in 1 CARTON (66215-401-01) > 10 mL in 1 VIAL
VELETRI
epoprostenol sodium
 INJECTABLE;INJECTION 022260 NDA Actelion Pharmaceuticals US, Inc. 66215-402 66215-402-01 1 VIAL in 1 CARTON (66215-402-01) > 10 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 1.5MG BASE/VIAL
Approval Date:Jun 27, 2008TE:RLD:Yes
Patent:8,318,802Patent Expiration:Mar 15, 2027Product Flag?YSubstance Flag?Delist Request?
Patent:8,598,227Patent Expiration:Feb 2, 2027Product Flag?Substance Flag?Delist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 0.5MG BASE/VIAL
Approval Date:Jun 28, 2012TE:RLD:Yes
Patent:8,318,802Patent Expiration:Mar 15, 2027Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Dow
Merck
Novartis
US Army
McKinsey
Express Scripts
Covington
Cipla
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot